FASTING IN A PILL? HOW SGLT2 INHIBITORS ARE "TRICKING" BIOLOGY INTO STAYING YOUNG
Vorschaubild von YouTube. Abspielen lädt den YouTube-Player.
Verlauf & EmpfehlungenAus
Zuletzt angesehene Inhalte in diesem Browser behalten. Dein Verlauf bleibt auf diesem Gerät und wird nicht an Harbor gesendet. Abgespielte Videos können auch passende Videoempfehlungen sortieren.
Merkliste & Verlauf öffnen →Über dieses Video
Creator-Beschreibung · OriginaltextTextsprache: Englisch
For years, SGLT2 inhibitors (like Jardiance and Farxiga) were known simply as tools to help the body flush excess sugar through the urine. But as of 2026, the narrative has shifted completely.
What was once a "diabetes drug" is now being recognized as one of the most potent tools in the geroscience toolkit.
The Evidence: Beyond Glucose Control Massive Randomized Controlled Trials (RCTs) like EMPA-REG and DAPA-HF delivered a shock to the medical community. The data showed that these drugs don’t just lower blood sugar—they provide significant protection for the heart and kidneys, even in people without diabetes.
Why are longevity specialists increasingly prescribing these "off-label" to healthy adults?
• The Fasting Mimetic: SGLT2 inhibitors essentially "trick" the body into a state that mimics caloric restriction and fasting. By lowering insulin levels and shifting the body toward fat oxidation, they trigger cellular repair pathways similar to those found in long-lived populations.
• All-Cause Mortality: The reduction in mortality across these trials was so consistent that many researchers believe we are looking at a true "geroprotector"—a compound that slows the underlying processes of aging itself. In massive clinical trials and recent meta-analyses, SGLT2 inhibitors have demonstrated a consistent and significant reduction in all-cause mortality (death from any cause), even among patients without diabetes.
• The reduction ranged from 13% to 32%, depending on the specific patient population (e.g., those with heart failure, kidney disease, or high cardiovascular risk).
•
• Organ Protection: The placebo-controlled data on heart failure prevention and kidney preservation is now considered overwhelming by the clinical community.
We are entering an era of "Precision Longevity," where we use validated pharmaceutical tools to mimic the survival signals of our ancestors. SGLT2 inhibitors represent a bridge between managing a disease and actively engineering a longer, healthier life.
North Texas Medical Anti Aging Center · 3 min · Quelle veröffentlicht: 2026-03-05
Zu Harbor hinzugefügt: 23.10.2026
Original auf YouTube ↗Automatisch eingeordnete Quelle. Creator-Aussagen sind keine unabhängige Evidenzprüfung und keine persönliche medizinische Beratung.